Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Generating Medical Discharge Report Drafts Via Artificial Intelligence (Letter)

12 de noviembre de 2026 actualizado por: Kepler University Hospital

A key process in intensive care is the creation of transfer reports. These summarize the essential aspects of the treatment to date and ensure that information is passed on to the next treatment team in a structured manner. They contain, among other things, diagnoses, relevant examination results, and therapeutic measures that have been carried out. The aim of a transfer report is to document the patient's medical history and the course of treatment to date in a concise and complete manner. Incomplete transfer reports can lead to repeated examinations, which can potentially delay further therapy and endanger the patient, as well as incurring additional costs.

In this context, a complete transfer report ensures continuity of treatment and contributes significantly to patient safety.

Transfer reports are created from a synthesis of a large number of documents. In addition to medical facts from tables and free-text summaries, physicians also draw on their experience to pass on relevant information to future treatment teams in the synthesis of detailed documentation. This process naturally requires a great deal of time and concentration in patients receiving intensive care.

Artificial intelligence methods, such as large language models (LLMs), could be used to learn how to create transfer reports and formulate drafts.

LLMs can convert unstructured free text into a structured form, thereby facilitating the report creation process. This would make it possible to generate a pre-formulated draft that doctors could then review and supplement.

At present, transfer reports are created by physicians with considerable effort and time. The methods currently available for automating report generation are limited to text modules that largely bundle data sources deterministically. Some of these methods are already commercially available, but they are not capable of creating individual reports beyond form letters.

The automatic analysis of unstructured text data falls within a subfield of AI known as natural language processing (NLP), which also includes language models (LLMs) such as ChatGPT and Gemini, which have been popular since 2022. A major milestone was reached with the development of the Transformer architecture in 2017, which, in addition to the availability of enormous amounts of training data (e.g., Wikipedia, news articles, or books), forms the basis for many groundbreaking language models. The effectiveness of these LLMs is limited for specific domains such as medicine, as the training data often lacks relevant characteristics such as complex terminology or writing styles. Adapting these models for clinical use to improve patient care, research, and medical education is a highly topical field of research. The most relevant foreign-language models include BioBERT, Meditron, and Med-PaLM. As of July 2024, there is only limited research on the development of German-language models, e.g., medBERT, BioGottBERT, and a few models that are not publicly available.

The sole use of LLMs is problematic due to non-reproducible results, lack of transparency, and bias in the models. Knowledge graphs (KGs) are used in medicine to represent and analyze complex information structures. The creation of a "robust digital patient twin" would be improved by the use of LLMs and KGs. This would allow the state of health to be assessed based on all digitally available clinical information (both structured and, in this project, now also unstructured). Recent studies confirm that adapted LLMs in the English language domain can produce summaries that are equivalent to or better than those produced by human experts, and that these are often difficult to distinguish from reports written by humans.

The legal framework for this results from a complex interaction of legal provisions from data protection law (with regard to health data), artificial intelligence law (AI Act), medical law (in particular hospital law), (medical) product law, medical professional law, and other relevant professional groups (e.g., nursing and pharmacy), as well as relevant civil and criminal law standards of care. In addition, there are fundamental rights requirements based on the ECHR and the EU Charter of Fundamental Rights. Data protection issues relating to the use of health data, in particular for research with AI systems, and professional law issues in connection with automated aggregation and presentation have already been examined in detail (as part of the SMARAGD project, FFG 872575).

Descripción general del estudio

Estado

Reclutamiento

Tipo de estudio

De observación

Inscripción (Estimado)

40000

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

Copia de seguridad de contactos de estudio

  • Nombre: Jens Meier, MD
  • Número de teléfono: 2158 +435768083
  • Correo electrónico: jens.meier@jku.at

Ubicaciones de estudio

    • Upper Austria
      • Linz, Upper Austria, Austria, 4020
        • Reclutamiento
        • Johannes Kepler University, Kepler University Hospital
        • Contacto:
        • Contacto:
          • Jens Meier, MD
          • Número de teléfono: 2158 +435768083
          • Correo electrónico: jens.meier@jku.at

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

Sí

Géneros elegibles para el estudio

Todos

Método de muestreo

Muestra no probabilística

Población de estudio

Patients treated in intensive care units.

Descripción

Inclusion Criteria:

  • Treated in intensive care units between 2008-11-01 to 2025-05-31 at the study center.

Exclusion Criteria:

  • Refusal to participate in scientific studies.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Modelos observacionales: OTHER
  • Perspectivas temporales: RETROSPECTIVE

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Quality of Discharge Report Drafts
Periodo de tiempo: 2008-11-01 to 2025-05-31

Quality of Discharge Report Drafts evaluated based on technical parameters and assessed by human experts.

Factual correctness: Accurate reproduction of e.g. diagnoses, medication versus hallucinations using Entity Matching Score (Percentage of correctly reproduced entities compared with the source data) and Hallucination Rate (Proportion of unverifiable statements).

Completeness: All relevant information is included using checklist compliance (proportion of required fields covered) and Recall against Reference Texts (comparison with physician-written letters, e.g. using ROUGE-L).

Clinical Validity: Recommendations must be evidence-based and consistent with clinical guidelines using guideline-adherence (e.g. rule-based systems or LLM-based assessments).

Structure is assessed with template compliance using NLP-based section recognition.

Data Protection: Degree of Anonymization using NER models. Comprehensibility: Clear, precise language without ambiguities using Readability Assessment.

2008-11-01 to 2025-05-31

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Traceability
Periodo de tiempo: 2008-11-01 to 2025-05-31

The data sources used to create text passages should be visualized so that the steps performed by the AI can be explained and traced. Traceability should also be evaluated by human experts.

2008-11-01 to 2025-05-31
Degree of Necessary Adjustments
Periodo de tiempo: 2008-11-01 to 2025-05-31

The degree of necessary adjustments to drafts should be evaluated proportionally as a percentage of the total text and based on the type of adjustments made by human experts (e.g., spelling errors, content corrections, additions).

2008-11-01 to 2025-05-31

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Investigadores

  • Investigador principal: Thomas Tschoellitsch, MD, Johannes Kepler University

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

1 de abril de 2026

Finalización primaria (Actual)

1 de abril de 2026

Finalización del estudio (Estimado)

1 de abril de 2029

Fechas de registro del estudio

Enviado por primera vez

25 de febrero de 2026

Primero enviado que cumplió con los criterios de control de calidad

12 de noviembre de 2026

Publicado por primera vez (Actual)

17 de noviembre de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

17 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

12 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • MEDI-DOK Letter

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir